NMT Medical
This article was originally published in The Gray Sheet
Executive Summary
Firm starts enrollment for multi-center UK BioStar Evaluation STudy (BEST) of next-generation college matrix patent foramen ovale (PFO) closure device, according to July 7 release. The trial will support a European CE mark, which NMT expects in the first half of 2006. The company is investigating the bio-absorbable device's ability to prevent migraine headaches, recurrent stroke and transient ischemic attack (1"The Gray Sheet" March 7, 2005, p. 29). BEST's data may aid, but will not be sufficient for gaining FDA approval, the company said...